


ABOUT > WORKSHOPS

- ABOUT SUMMIT >
- WORKSHOPS >
- SPEAKERS >
- POSTER SESSION >
- EVENT GUIDE >
- CONTENT LIBRARY >



“I’m excited to meet with experts working in both industry and academia and exchanging ideas. Understanding how we can improve our preclinical models to increase success rates in the clinic is critical.”

Helen Tomkinson, AstraZeneca

“I’m most looking forward to see emerging data on the use of innovative mouse tumour models to profile novel cancer immuno-therapies. It will be incredibly useful to learn how industry leaders are using preclinical mouse models to translate their data on novel therapeutics into the clinic.”

Markus Reschke, Boehringer Ingelheim

Workshop A

4th December, 2018

09.00 - 12.00

Using Translational Modelling to Evaluate Preclinical Tumour Models

Discovery and development of cancer treatments (e.g. radiotherapy, chemotherapy, cell-directed targeted therapy, immune therapy) require PK/PD modelling for robust experimental design and unambiguous data interpretation.

This short course will introduce how translational PK/PD modeling for chemotherapy and cell-directed targeted therapy can be used to relate preclinical data with clinical response. We will also discuss the basics of PK/PD modelling that are relevant to evaluating novel immuno-oncology treatments. It will help attendees to learn about dose selection, estimation of therapeutic window, and translational sciences based on PK/PD modeling.

- How do we define the quantitative relationship between preclinical efficacy and clinical activity for these treatments?
- Is it possible to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success?
- How to apply translational modelling framework to best support drug projects? Where does it add value?
- Which ideas can be borrowed to support immuno-oncology projects?



Workshop Leader

Tao You
PK/PD Modeller & Data Scientist
Beyond Consulting Ltd

Workshop B

4th December, 2018

13.00 - 16.00

Humanised Mice Models as a Translational Tool for Immuno-Onocology

Recent breakthroughs involving humanized mice have elevated the translational quality of these models within preclinical research. As such these models have become highly relevant for fundamental research to understand the function of the human immune system and in assessing cancer immunology and immunotherapies.

This workshop will explore the different strategies of immune system humanization in mice as well as to review challenges, insights, and future directions for mouse and humanized models within oncology.

Topics to be covered:

- State of the art of humanized mice
- Immune reactivity / responses in humanized mice
- What did we learn from viral infection studies in humanized mice
- State of the art of humanized mice for studying tumours



Workshop Leader
Roberto Speck
Professor
University Hospital of Zurich

[NEXT PAGE: SPEAKERS](#)

[CLICK HERE >](#)



OUR CONTACT DETAILS

T: +44 (0)20 3141 8700
E: info@hansonwade.com


VENUE DETAILS

DoubleTree by Hilton Hotel
London - Docklands Riverside
265 Rotherhithe Street
London
SE16 5HW
United Kingdom

ABOUT US

Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

LOCATION



SEARCH

ORGANISED BY



hansonwade

[Terms & Conditions](#)

© Copyright 2018 Hanson Wade | Design and site by [Event Engine](#) | Hanson Wade Limited is registered in England & Wales, number 06752216. Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.